Obesity drug dropped as 'too risky'

GPs warn treatment options should not be limited where a benefit is shown.

Dr Haslam: 'benefits lost'
Dr Haslam: 'benefits lost'

GPs have expressed disappointment at the suspension of the weight-loss drug rimonabant.

Dr Ian Campbell, a GP in Nottingham and medical director of the charity Weight Concern, said prescribers are aware of the drug's adverse effects on anxiety and depression and monitored patients closely.

'It is disappointing for those patients for whom the drug is working,' he said.

Around 20,000 patients in the UK have been treated with rimonabant, marketed as Acomplia, but last week the European Medicines Agency (EMEA) decided that its benefits no longer outweigh its risks.

Prescribers should not issue any new prescriptions for the drug, the EMEA said.

Patients do not need to stop treatment immediately, but those who wish to stop can do so at any time, the EMEA advised.

Dr David Haslam, a GP in Hertfordshire and clinical director of the National Obesity Forum, said the move was 'a great shame'.

'I have patients whose diabetes is well controlled who have benefited from rimonabant and that benefit will end when their treatment ends.'

The drug's manufacturer Sanofi-Aventis said it was complying with the EMEA's recommendation and would provide additional evidence for re-evaluation of the drug's benefit-risk profile in patients with diabetes and cardiovascular disease.

The EMEA said its assessment showed an increased risk of psychiatric disorders in patients taking rimonabant. In addition, the agency said that the drug's effectiveness in clinical practice had been found to be more limited than was expected.

Sir Michael Rawlins, chairman of NICE, told GP that the institute had withdrawn its June guidance, which recommended the drug for third-line use after orlistat and sibutramine.

tom.moberly@haymarket.com.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

GP-led sites behind almost three quarters of COVID-19 jabs in England

GP-led sites behind almost three quarters of COVID-19 jabs in England

GP-led vaccination sites have delivered nearly three quarters of COVID-19 vaccine...

GPs should ignore calls to throw away usable COVID-19 vaccine, says RCGP

GPs should ignore calls to throw away usable COVID-19 vaccine, says RCGP

Suggestions that vaccination sites should throw away usable doses of COVID-19 vaccine...

GPs urged to use influence to dispel COVID-19 vaccine myths and boost BAME uptake

GPs urged to use influence to dispel COVID-19 vaccine myths and boost BAME uptake

GPs have been encouraged to use their ‘huge influence’ to bust misinformation around...

Six in 10 over-80s vaccinated against COVID-19 as figures expose regional variation

Six in 10 over-80s vaccinated against COVID-19 as figures expose regional variation

Six in 10 people aged over 80 in England received a first dose of COVID-19 vaccine...

Summary of changes to the GP contract 2021/22

Summary of changes to the GP contract 2021/22

The BMA and NHS England have agreed minor changes to the GP contract for 2021/22....